1. What Is the Molecular Imaging Market?
The Molecular Imaging Market covers the imaging technologies that visualise cellular and molecular processes in living tissue, primarily positron emission tomography, single-photon emission computed tomography, and hybrid systems combined with CT or MRI, supplied to nuclear medicine departments and research institutions. Nuclear medicine physicians use molecular imaging to assess physiological function including metabolism, receptor binding, and perfusion that anatomical imaging cannot reveal. The market serves oncology staging and treatment monitoring, neurology including Alzheimer's and Parkinson's diagnosis, cardiology perfusion imaging, and theranostics that pair diagnostic and therapeutic radiopharmaceuticals. It includes the scanners, the radiopharmaceuticals, and the quantification software, with demand driven by expanding theranostic programmes and novel PET tracers extending clinical indications.
2. Molecular Imaging Market Size & Forecast
3. Emerging Technologies
- PSMA PET imaging quantifying prostate-specific membrane antigen expression for prostate cancer staging.
- Amyloid and tau PET enabling molecular Alzheimer's staging for disease-modifying therapy patient selection.
- Theranostic radiopharmaceuticals pairing diagnosis and targeted radioligand therapy at the same molecular target.
- PET-MR hybrid systems combining metabolic and soft-tissue information for complex oncology and neurological cases.
Similar technologies are also transforming adjacent markets. Learn more in our Mri Coil Market.
4. Key Market Opportunity
The largest near-term opportunity in the Molecular Imaging market lies in nuclear medicine departments expanding PET capacity for theranostic patient selection alongside radiopharmaceutical therapy. A second, faster-growing opportunity lies in academic medical centres adding novel PET tracers for Alzheimer's, neurodegeneration, and specialised oncology programmes. As adoption broadens, the addressable opportunity is expanding from early deployments toward wider commercial use, with Asia Pacific positioned for the most rapid growth through 2034.
5. Top Companies in the Molecular Imaging Market
The following organisations hold leading positions in the Molecular Imaging Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Siemens Healthineers
- GE HealthCare
- Philips
- United Imaging Healthcare
- Curium Pharma
- Lantheus Holdings
- POINT Biopharma
- Novartis Radioligand Therapy
- Eckert and Ziegler
- Noria Therapeutics
6. Market Segmentation
The Molecular Imaging Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Modality | PETSPECTPET-MRSPECT-CT |
| By Application | OncologyNeurologyCardiologyTheranostics |
| By Radiopharmaceutical | FDGPSMAAmyloidPeptide |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Molecular Imaging Market trajectory over the forecast period:
Theranostics Has Become the Most Dynamic Growth Dimension, Pairing a Diagnostic Radiopharmaceutical.Theranostics has become the most dynamic growth dimension, pairing a diagnostic radiopharmaceutical with a matched therapeutic radioligand to image and treat the same molecular target. Novartis's Lutathera and Pluvicto demonstrate the clinical utility of radiopharmaceutical therapy in neuroendocrine tumours and prostate cancer. The FDA approval of PSMA-targeted imaging and therapy has expanded demand for PET imaging of prostate cancer and created a new treatment modality. The theranostic concept links the diagnostic and therapeutic radiopharmaceutical pipeline, creating demand for imaging that accompanies radiotherapy. This theranostic expansion is the primary driver differentiating molecular imaging growth from general diagnostic equipment.
Novel PET Tracers Beyond FDG Are Expanding the Clinical Indication Base.Novel PET tracers beyond FDG are expanding the clinical indication base, as amyloid PET for Alzheimer's staging, tau PET for neurodegeneration, and PSMA PET for prostate cancer provide diagnostic utility unavailable from anatomical imaging. The US FDA approval of Amyvid for amyloid imaging and PSMA agents has opened these indications in clinical practice. These approvals create new recurring radiopharmaceutical demand alongside scanner utilisation.
SPECT Remains Widely Used for Cardiac Perfusion.SPECT remains widely used for cardiac perfusion, as its lower equipment cost and availability make it the modality of choice for myocardial perfusion imaging in many facilities. While PET cardiac imaging offers improved sensitivity, SPECT's installed base and lower cost sustain its role in non-academic cardiology.
For related market intelligence, see the Diagnostic Imaging Market.
8. Segmental Analysis
By modality, the PET segment dominated the Molecular Imaging Market in 2025, as positron emission tomography represents the largest-growing and highest-value molecular imaging technology.
By application, the theranostics segment is projected to register the highest CAGR in the Molecular Imaging Market through 2034, as radiopharmaceutical therapy approval expands the diagnostic imaging requirement for patient selection, driving the fastest-growing application category within the market.
9. Regional Analysis
Regional demand patterns across the Molecular Imaging Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Molecular Imaging Market in 2025, accounting for the largest share of revenue. Moreover, the United States leads through the highest PET scanner density, the most advanced radiopharmaceutical approval pipeline, and the early clinical adoption of novel tracers including PSMA and amyloid agents. In addition, theranostic therapy approval by the FDA has created the most developed theranostic clinical practice globally. The concentration of academic nuclear medicine programmes and radiopharmacy networks anchors revenue leadership.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Molecular Imaging Market through 2034. The primary driver is China's rapid expansion of nuclear medicine departments with PET CT scanners and growing radiopharmacy infrastructure, alongside the entry of United Imaging Healthcare with competitive domestic systems. Moreover, Japan and South Korea add further nuclear medicine volume. The combination of these demand drivers and an expanding base positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Molecular Imaging Market was valued at USD 4.25 Bn in 2025 and is projected to reach USD 9.53 Bn by 2034, growing at a CAGR of 9.4% over the 2026–2034 forecast period.
The Molecular Imaging Market is projected to grow at a CAGR of 9.4% from 2026 to 2034.
North America dominated the Molecular Imaging Market in 2025, accounting for the largest share of revenue.
The leading companies in the Molecular Imaging Market include Siemens Healthineers, GE HealthCare, Philips, United Imaging Healthcare, Curium Pharma, Lantheus Holdings, POINT Biopharma, Novartis Radioligand Therapy, Eckert and Ziegler, Noria Therapeutics.
Theranostics has become the most dynamic growth dimension, pairing a diagnostic radiopharmaceutical.
By modality, the PET segment dominated the Molecular Imaging Market in 2025, as positron emission tomography represents the largest-growing and highest-value molecular imaging technology.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.